Once again, my question was:
"Would you, if ill with Covid, take a drug that had (in its research stages) utilized human stem cells from an aborted fetus?" And yes, I added any other life threatening disease because you implied that covid is a mild infection.
Did I randomly search and post an "I got ya?" Well I did research, why wouldn't I? And no, it wasn't for the sake of an "I got ya" it was in the spirit of conversation. That said, I did read articles that were interesting concerning the fight against covid-19. Isn't that what anybody taking part in a conversation does? Try to expand their knowledge on the subject of discussion? When you believed JLM researched Covid-19 and related sepsis you stated that you were "glad" that he had looked something up. Why then if I look something up, is that met with hostility?
From what I read in the multiple articles I found, MSC cells are not limited in their capacity, they are being utilized in studies for Covid-19, ALS, inflammatory diseases and sepsis. One such study related to Covid-19 taking place right here in Canada, which is exciting. I'll provide some links below.
I'm not upset that you "got me" whatever that means. I simply posed a hypothetical question for the sake of starting a conversation. Isn't that the purpose of a forum? To have discussion? This is a thread about Covid-19 right? Are questions and subsequent discussions about covid-19 not allowed? Or is this just a place for people to try to outdo one another with brash insults.
Here are some links:
Experimental Stem Cell Therapy a Potential Weapon in COVID-19 Fight
Now, a team based at The Ottawa Hospital is redeploying lessons learned from the world’s first safety trial assessing the use of mesenchymal stem/stromal cells (MSCs) for treating runaway inflammation in patients with severe sepsis to treat the intense lung inflammation that causes Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients.
The safety phase will use bone-marrow derived MSCs Stewart’s team has banked in their Ottawa lab, and MSCs from the umbilical cord provided through a partnership the Center for Regenerative Therapies (CRTD) in Dresden, Germany will be used to assess the maximum feasible tolerated dose, as well as efficacy. MSCs culled from umbilical cord are similar to those derived from bone marrow but may have superior anti-inflammatory function, and are more readily available during a global pandemic, Stewart notes.
https://oirm.ca/news_events/stem-cell-trial-covid19/
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis
https://pubmed.ncbi.nlm.nih.gov/20937945/
Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials
Stem cells are likely the most promising agent for the treatment of degenerative and ischemic diseases due to their self-renewal and multilineage differentiation capacity. The most exciting aspect of these unique cells is their potential therapeutic impact for regenerative medicine [1, 2]. The best studied type of stem cell is the hematopoietic stem cell (HSC), and transplantation of these tissue-specific stem cells have now become standard-of-care for numerous indications [3]. Over 50 years in the making, the success of HSC transplantation is illustrative of the paradigm for stem cell therapy: replacement and regeneration of pathological endogenous tissue with autologous or 3rd party/allogeneic stem cells. While research in stem cell biology is mainly focused on this goal, an unexpected new avenue of clinical application has emerged for the mesenchymal stem cell (MSC) as an immunotherapeutic agent. A type of somatic progenitor/stem cell, the MSC is capable of multilineage differentiation. However, in recent years, consistent reports on its immunomodulatory properties have opened up the use of these cells for indications other than regenerative medicine. The therapeutic application of MSCs in immune/inflammatory contexts may be more efficacious than traditional indications for regenerative medicine, since engraftment of infused/transplanted stem cells—which have proved surprisingly difficult to achieve [4]—appears not to be necessary for efficacy [5]. In this review, we specifically focus on this non-traditional application of a tissue-specific stem cell, and highlight important findings and trends in this exciting area of stem cell therapy.
MSCs were first isolated from the adult bone marrow (BM), and distinguished from marrow hematopoietic cells by their adherent nature in in vitro cell cultures and fibroblastic morphology [6, 7]. The function of BMMSCs was initially thought to be limited to supporting hematopoiesis; indeed, one of the first clinical use of these progenitor/stem cells was to enhance HSC engraftment [8]. Since these early reports, MSCs have been demonstrated to exist in a wide range of adult and fetal organs/tissues [9], and popular sources for isolation other than the BM include adipose tissue, umbilical cord blood, umbilical cord and placenta. In 2006, the International Society for Cellular Therapy (ISCT) established the following unified and minimal criteria to define MSCs [10].
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095977/